Fifth Third Bancorp Has $6.56 Million Stock Position in Humana Inc. (NYSE:HUM)

Fifth Third Bancorp lowered its stake in Humana Inc. (NYSE:HUM – Free Report) by 8.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,522 shares of the insurance provider’s stock after selling 1,254 shares during the quarter. Fifth Third Bancorp’s holdings in Humana were worth $6,564,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Norges Bank bought a new position in Humana during the 4th quarter worth about $690,516,000. Starboard Value LP bought a new position in Humana during the 1st quarter worth about $421,332,000. Price T Rowe Associates Inc. MD increased its holdings in Humana by 12.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,623,130 shares of the insurance provider’s stock worth $3,904,491,000 after purchasing an additional 831,057 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Humana by 63.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,692,255 shares of the insurance provider’s stock worth $821,065,000 after purchasing an additional 654,681 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in Humana during the 1st quarter worth about $151,766,000. Institutional investors and hedge funds own 93.21% of the company’s stock.

Get Humana alerts:

Humana Trading Down 2.5 %

Shares of HUM stock opened at $430.14 on Friday. The firm has a 50 day moving average price of $491.84 and a two-hundred day moving average price of $497.53. The company has a quick ratio of 1.39, a current ratio of 1.39 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $53.74 billion, a PE ratio of 17.47, a price-to-earnings-growth ratio of 1.15 and a beta of 0.67. Humana Inc. has a 12-month low of $429.63 and a 12-month high of $571.30.

Humana (NYSE:HUM – Free Report) last issued its quarterly earnings data on Wednesday, April 26th. The insurance provider reported $9.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.25 by $0.13. The firm had revenue of $26.74 billion during the quarter, compared to the consensus estimate of $26.40 billion. Humana had a net margin of 3.26% and a return on equity of 21.04%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the business posted $8.04 earnings per share. As a group, analysts predict that Humana Inc. will post 28.28 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Friday, June 30th will be given a $0.885 dividend. The ex-dividend date is Thursday, June 29th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.82%. Humana’s payout ratio is 14.38%.

Insider Activity

In other news, CFO Susan M. Diamond sold 4,156 shares of Humana stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $526.28, for a total value of $2,187,219.68. Following the completion of the sale, the chief financial officer now directly owns 3,931 shares in the company, valued at $2,068,806.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.32% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft increased their target price on Humana from $562.00 to $568.00 in a report on Thursday, April 27th. SVB Securities decreased their price objective on Humana from $640.00 to $600.00 in a report on Thursday, April 27th. JPMorgan Chase & Co. cut Humana from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $576.00 to $540.00 in a report on Friday. Barclays decreased their price objective on Humana from $620.00 to $585.00 in a report on Monday, June 19th. Finally, StockNews.com began coverage on Humana in a report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $598.56.

Humana Company Profile

(Free Report)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories

• Five stocks we like better than Humana
• MarketBeat Week in Review – 7/3 – 7/7
• Pfizer Just Invested $25 million In This Biotech
• Cracks In The Labor Market? Not Yet, But They’re Coming 
• Levi’s: Buy On The Dip Or Downtrend In Play? 
• Who Wins And Who Loses With China’s Metal Restrictions

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.